Skip to content

Study of ABSORB Stent in Acute Myocardial Infarction

Study of ABSORB Stent in Acute Coronary Syndrome

Status
UNKNOWN
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT02071342
Acronym
ABSORB-ACS
Enrollment
300
Registered
2014-02-25
Start date
2013-09-30
Completion date
2015-09-30
Last updated
2014-02-25

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Acute Myocardial Infarction, Artery; Deformity, Coronary (Acquired)

Keywords

acute myocardial infarction, bioresorbable vascular scaffold, percutaneous coronary intervention

Brief summary

The aim of our study is to evaluate the clinical outcomes at 30 days and 1 year (cardiac death, myocardial infarction, target lesion revascularization (TLR), target vessel revascularization (TVR), thrombosis of the device in patients who are undergoing angioplasty in myocardial infarction and in which bioabsorbable stent was implanted (BVS). Additionally, we will evaluate the acute recoil after implantation of bioabsorbable stents. A 24 months follow-up , by means of coronary angiography accompanied by QCA and assessment with intracoronary ultrasound (IVUS) and VH (virtual histology) is scheduled.

Detailed description

The drug -eluting stents (drug eluting stents , DES) are currently used routinely in the course of coronary angioplasty ( percutaneous coronary intervention , PCI ) and have significantly reduced the incidence of adverse events during follow-up in the medium and long term . However, the persistence of the metal structure of these devices within the coronary artery over time adds no additional benefit but , on the contrary , it is potentially harmful because it may predispose to coronary thrombosis even after years of implantation, can alter the structure of the vessel for remodeling phenomena, can decrease a coronary vasomotion and reducing the possibilily of a future surgery. The recent development of new devices such as bioabsorbable vascular scaffold BVS release of antiproliferative drug ( everolimus ), could provide new clinical advantages especially in patients who are revascularized during acute myocardial infarction. These patients are at higher risk of MACE and stent thrombosis late . The aim of our study is to evaluate the clinical outcomes conventional to 30 days and 1 year, such as cardiac death, myocardial infarction, target lesion revascularization(TLR ), target vessel revascularization (TVR ), thrombosis of the device in patients who undergo angioplasty in the course of acute coronary syndrome and in which it was implanted bioabsorbable stent ( BVS ). The acute recoil after implantation of bioresorbable vascular scaffold will also be assessed Finally, a follow-up of 24 months we will conduct, by means of coronary angiography accompanied by QCA and IVUS with VH .

Interventions

PROCEDUREangioplasty

patients with acute coronary syndrome and coronary angioplasty with bioresorbable vascular scaffold.

Sponsors

Umberto I Hospital, Frosinone Italy
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* patients older than 18 years with acute coronary syndrome (STEMI and NSTEMI) will be enrolled

Exclusion criteria

* patients with these characteristics will be excluded: cardiogenic shock (defined as systolic blood pressure less than 80 mmHg for more than 30 minutes or the need for compressors or intravenous-intraaortic balloon counterpulsation), history of bleeding diathesis, history of leukopenia , thrombocytopenia, or severe hepatic or renal dysfunction, a non-cardiac disease associated with a life expectancy of less than one year, participating in another study, or not able to give informed consent due to a prolonged resuscitation cardiopulmonary.

Design outcomes

Primary

MeasureTime frameDescription
MACE (Death, MI, TLR and TVR)One year after index procedureMACE at 30 days and 1 year (Death, MI, TLR and TVR) and thrombosis of the device in patients with acute coronary syndrome undergoing PCI with stenting bioresorbable

Secondary

MeasureTime frameDescription
Acute stent RecoilWithin ten minutes after scaffold implantationEvaluation of acute recoil after implantation of bioabsorbable stent (BVS).

Other

MeasureTime frameDescription
conformabilityimmediately after implantation of the deviceEvaluation of the conformability of the stent and the vessel curvature and angle before and after implantation of the device

Countries

Italy

Contacts

Primary ContactMaurizio Menichelli, MD
menichelli747@yahoo.com+393382642317

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026